Equities research analysts predict that Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) will post $2.23 million in sales for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for Tetraphase Pharmaceuticals’ earnings, with estimates ranging from $1.60 million to $2.90 million. Tetraphase Pharmaceuticals reported sales of $2.53 million during the same quarter last year, which indicates a negative year-over-year growth rate of 11.9%. The business is scheduled to report its next earnings results on Tuesday, March 5th.
According to Zacks, analysts expect that Tetraphase Pharmaceuticals will report full year sales of $16.98 million for the current financial year, with estimates ranging from $16.20 million to $17.88 million. For the next fiscal year, analysts anticipate that the company will post sales of $16.71 million, with estimates ranging from $11.00 million to $31.55 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Tetraphase Pharmaceuticals.
Several research firms recently issued reports on TTPH. Zacks Investment Research raised Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, January 23rd. Robert W. Baird reissued a “buy” rating and issued a $3.00 target price on shares of Tetraphase Pharmaceuticals in a research note on Monday, January 7th. Finally, B. Riley began coverage on Tetraphase Pharmaceuticals in a research note on Friday, January 4th. They issued a “buy” rating and a $3.00 target price on the stock. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and eight have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $5.36.
NASDAQ TTPH opened at $1.20 on Thursday. The stock has a market capitalization of $64.35 million, a P/E ratio of -0.46 and a beta of 2.89. Tetraphase Pharmaceuticals has a 1 year low of $1.01 and a 1 year high of $4.49.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. boosted its position in Tetraphase Pharmaceuticals by 3.7% during the 2nd quarter. BlackRock Inc. now owns 4,172,314 shares of the biopharmaceutical company’s stock valued at $14,895,000 after acquiring an additional 149,866 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its position in Tetraphase Pharmaceuticals by 9.2% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 275,630 shares of the biopharmaceutical company’s stock valued at $984,000 after acquiring an additional 23,337 shares in the last quarter. Canada Pension Plan Investment Board boosted its position in Tetraphase Pharmaceuticals by 400.0% during the 3rd quarter. Canada Pension Plan Investment Board now owns 250,000 shares of the biopharmaceutical company’s stock valued at $690,000 after acquiring an additional 200,000 shares in the last quarter. Marshall Wace LLP bought a new stake in Tetraphase Pharmaceuticals during the 3rd quarter valued at approximately $927,000. Finally, Alambic Investment Management L.P. boosted its position in Tetraphase Pharmaceuticals by 392.6% during the 3rd quarter. Alambic Investment Management L.P. now owns 87,704 shares of the biopharmaceutical company’s stock valued at $242,000 after acquiring an additional 69,900 shares in the last quarter. 42.90% of the stock is currently owned by institutional investors.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.
Recommended Story: Conference Calls
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.